Skip to main content
. Author manuscript; available in PMC: 2015 Nov 1.
Published in final edited form as: JAMA Intern Med. 2014 Nov 1;174(11):1736–1745. doi: 10.1001/jamainternmed.2014.4052

Table 3.

Primary and Secondary Outcomes from Time-Line Follow-Back

BI-B SAR MSO Total
Days of use of the primary drug of abuse in the past 30 days at
Baseline 14.8 (11.23) 16.3 (11.42) 15.5 (11.34)
3 month Visit 9.4 (11.68) 10.9 (12.09) 10.5 (11.93) 10.3 (11.91)
6 Month Visit 8.2 (11.19) 9.7 (11.63) 9.8 (12.14) 9.2 (11.68)
12 Month Visit 8.6 (11.17) 7.9 (11.11) 8.5 (11.40) 8.3 (11.22)
Days of drug use in the past 30 days at
Baseline 16.4 (11.03) 18.5 (10.93) 17.4 (11.03)
3 Month Visit 11.9 (12.05) 13.7 (12.36) 13.0 (12.11) 12.9 (12.19)
6 Month Visit 10.8 (12.05) 12.5 (12.20) 12.1 (12.61) 11.8 (12.31)
12 Month Visit 10.7 (11.82) 10.9 (12.08) 11.0 (12.24) 10.9 (12.04)
Days of heavy drinking in the past 30 days at
Baseline 4.6 (8.38) 4.3 (8.07) 4.4 (8.22)
3 Month Visit 2.9 (6.72) 3.3 (7.19) 3.2 (7.16) 3.1 (7.03)
6 Month Visit 3.3 (7.15) 2.7 (6.33) 2.6 (6.10) 2.9 (6.54)
12 Month Visit 3.3 (7.30) 2.7 (6.57) 3.2 (7.26) 3.1 (7.05)

Data shown are Mean (S.D.)